HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis.

By C. Ndiaye, M. Mena, L. Alemany, M. Arbyn, X. Castellsagué, L. Laporte, X. Bosch, S. de Sanjosé, H. Trottier. The Lancet Oncology, 2014

666 citations recorded by the source corpus.

Subfields: Epidemiology, Otorhinolaryngology, Periodontics

View Paper: https://www.semanticscholar.org/paper/1355a4024e03052b5df01ee2d732f0ed06111138

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Chi
2. T. Day
3. B. Neville
4. M. El-Deiry
5. K. Higgins
6. C. Steuer
7. N. Saba
8. J. Parks

Citations in the corpus

• An update on larynx cancer (2017, methodology): “It is estimated that the prevalence of HPV ranges from 20% to 30% in laryngeal cancer; however, this percentage varies widely between studies and depends on the detection method used.(17,18) More work is needed to determine the clinical relevance of HPV/p16-positive status in laryngeal cancer, as th”
• Oral cavity and oropharyngeal squamous cell carcinoma—an update (2015, background): “In contrast, for OC-SCC, high-risk HPV DNA prevalence has been reported to be highest in Asia (25% for HPV-16).(72) Determining the HPV-attributable fraction of HN-SCC is somewhat problematic because of confounding factors (especially from tobacco use) and limitations in methodology.”